ArticleTranslational research : the journal of laboratory and clinical medicine2017
Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.
Article in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- The landscape of allele-specific expression in human kidneys.Science advances · 2026Article
- Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases.Immunobiology · 2025Review
- Integrating Single-Cell RNA-Seq and ATAC-Seq Analysis Reveals Uterine Cell Heterogeneity and Regulatory Networks Linked to Pimpled Eggs in Chickens.International journal of molecular sciences · 2024Article
- Interferon-α as a biomarker to predict renal outcomes in lupus nephritis.Lupus science & medicine · 2024Article
- Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis.Lupus science & medicine · 2024Article
- Urine Proteomics Link Complement Activation with Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients.Seminars in arthritis and rheumatism · 2023Article
- Complement therapeutics are coming of age in rheumatology.Nature reviews. Rheumatology · 2023Review
- Kidney diseases.Immunological reviews · 2023Review
- Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis.Kidney international · 2022Article
- Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Expert Perspective: An Approach to Refractory Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis.Metabolites · 2022Article
- Immune gene expression and functional networks in distinct lupus nephritis classes.Lupus science & medicine · 2022Article
- Epigenome-wide association study and network analysis for IgA Nephropathy from CD19Epigenetics · 2021Article
- Expanding the Role of Complement Therapies: The Case for Lupus Nephritis.Journal of clinical medicine · 2021Review
- Prediction of prognosis and renal outcome in lupus nephritis.Lupus science & medicine · 2020Review
- Rethinking Lupus Nephritis Classification on a Molecular Level.Journal of clinical medicine · 2019Article
- Management of refractory lupus nephritis: challenges and solutions.Open access rheumatology : research and reviews · 2019Review
- Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis.Annals of the rheumatic diseases · 2018Article
- Induction Therapy for Lupus Nephritis: the Highlights.Current rheumatology reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
The consequences of treatment for the kidney at the molecular level have not been explored in human lupus nephritis (LN). In this investigation, changes in intrarenal transcript expression were measured and correlated with response in a LN cohort that underwent serial kidney biopsies. The intrarenal transcript expression of 19 patients with proliferative LN (Class III or IV) was measured at diagnostic biopsy (Bx1) and after induction therapy was completed (Bx2) using Nanostring technology. Patients were segregated by clinical response into complete responders (n = 5, CR) or nonresponders (n = 4, NR). Transcript expression for each biopsy was compared with normal controls (n = 4), and the change in expression was compared in each responder group and between groups. Compared with controls, the CR group had 21 and 28, whereas NR had 45 and 103 differentially-expressed transcripts at Bx1 and Bx2, respectively. The profiles of these differentially-expressed genes indicated that the type I and II interferon, alternative complement and T cell signaling pathways discriminated CR from NR. Comparing the change in transcript expression from Bx1 to Bx2 revealed a 5-gene signature that differentiated NR from CR and included increased IL1RAP and FCAR in NR and increased NCAM1 in CR. In summary, molecular imaging of serial kidney biopsies from LN patients shows several immune and inflammatory pathways that are dysregulated in the kidneys during active disease that may serve as therapeutic targets to improve clinical response. This approach to LN biomarker development may facilitate personalized medicine in LN and improve long-term kidney outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.